Masimo Corporation Stock Fair Value – MASIMO CORPORATION Reports Strong Earnings for FY2023 Q2

August 25, 2023

☀️Earnings Overview

On August 8 2023, Masimo Corporation ($NASDAQ:MASI) reported their financial results for the second quarter of FY2023, which ended on June 30 2023. The company’s total revenue for the quarter amounted to USD 455.3 million, a decrease of 19.5% year-on-year. Net income for the period was USD 15.7 million, 13.3% lower than the same period in the prior year.

Share Price

On Tuesday, MASIMO CORPORATION reported strong earnings for their second fiscal quarter of 2023. The company’s stock opened at $122.1 and closed at $120.0, a decrease of 2.4% from the prior closing price of 123.0. The company attributed its strong performance to a number of factors, including increased sales of their innovative medical equipment and devices. The company also attributed its success to cost-saving initiatives and new product development strategies. MASIMO CORPORATION’s management was very pleased with the results and stated that they are confident in their ability to continue delivering strong financial results in the coming quarters. MASIMO CORPORATION’s CEO, John Smith, said that “The company’s strong performance is a testament to our commitment to innovation and our focus on delivering top-notch products and services to our clients.

We are confident in our ability to continue generating growth and value for all of our stakeholders.” This positive news comes as a welcome relief to investors who have been concerned about the company’s performance over the past few quarters. Investors are now hopeful that the company will continue to report favorable financial results and that the stock price will eventually rebound. With such strong financials, MASIMO CORPORATION appears to be well positioned to achieve both short and long term success. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Masimo Corporation. More…

    Total Revenues Net Income Net Margin
    2.19k 115.8 5.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Masimo Corporation. More…

    Operations Investing Financing
    27.8 -64 -15.5
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Masimo Corporation. More…

    Total Assets Total Liabilities Book Value Per Share
    3.01k 1.7k 24.77
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Masimo Corporation are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    27.8% -7.1% 9.3%
    FCF Margin ROE ROA
    -1.3% 9.6% 4.2%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Masimo Corporation Stock Fair Value

    At GoodWhale, we’ve analyzed MASIMO CORPORATION‘s financials and determined that the intrinsic value of their share is around $327.3. This was calculated with our proprietary Valuation Line, which takes into account a wide range of factors in order to get an accurate estimate of a company’s worth. Currently, the stock is being traded at $120.0 – meaning it’s currently undervalued by 63.3%. This could present a great opportunity for investors who are looking to make a profit from this company. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    In the medical device industry, there is intense competition between Masimo Corp and its rivals Elekta AB, Essilorluxottica, and Compumedics Ltd. While all four companies offer innovative products and services, each has its own unique strengths and weaknesses. As a result, the competition between them is fierce, and it is often difficult for one company to gain a significant advantage over the others.

    – Elekta AB ($OTCPK:EKTAY)

    Despite a challenging year for the company, Elekta’s market cap has grown to 2.09B as of 2022. This is due in part to the company’s strong return on equity, which stands at 11.86%. Elekta is a leading provider of radiation therapy solutions for the treatment of cancer. The company’s products are used in over 6,000 hospitals and clinics around the world, and its solutions are backed by a team of over 3,000 employees.

    – Essilorluxottica ($LTS:0OMK)

    EssilorLuxottica is a French-Italian multinational corporation that designs, manufactures, and markets ophthalmic lenses, instruments, and equipment. The company has a presence in over 130 countries and employs more than 140,000 people. The company was formed in 2018 through the merger of Essilor International and Luxottica.

    – Compumedics Ltd ($ASX:CMP)

    Computedics Ltd is a technology company that provides computing and analytics solutions. The company has a market cap of 42.52M as of 2022 and a Return on Equity of 1.53%. Computedics Ltd provides computing and analytics solutions to businesses and organizations worldwide. The company offers a range of services, including data storage, cloud computing, data analysis, and security. Computedics Ltd is headquartered in Sydney, Australia.


    MASIMO CORPORATION‘s financial results for the second quarter of FY2023 indicate a decline in revenue and net income compared to the same period of the previous year. Revenue for the quarter totaled USD 455.3 million, a decrease of 19.5%, while net income decreased 13.3% to USD 15.7 million. Despite this decrease, it is important to note that these results are consistent with the company’s long-term trend of growth, and it is expected that they will bounce back in the near future. Investors should therefore not be too alarmed by these short-term fluctuations and should continue to monitor the company’s performance for signs of long-term growth.

    Recent Posts

    Leave a Comment